Increased SULT1E1 activity in HepG2 hepatocytes decreases growth hormone stimulation of STAT5b phosphorylation

Steroids

Volumn 74, Issue 1, 2009, Pages 20-29

  Li, Li ^a   He, Dongning ^a   Wilborn, Teresa W ^b   Falany, Josie L ^a   Falany, Charles N ^a  

^a University of Alabama at Birmingham   (United States)

^b SAMFORD UNIVERSITY   (United States)

Author keywords

Estradiol; Growth hormone; Insulin like growth factor 1; STAT5b; Sulfotransferase; SULT1E1

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; GROWTH HORMONE; JANUS KINASE 2; SOMATOMEDIN C; STAT5B PROTEIN; SULFOTRANSFERASE; SULFOTRANSFERASE 1E1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SULFATION; TRANSCRIPTION INITIATION;

ANIMALS; CELL LINE, TUMOR; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; GENE EXPRESSION REGULATION; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, INBRED CFTR; MICE, KNOCKOUT; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; SULFOTRANSFERASES;

ANIMALIA;

EID: 57249089049     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2008.09.002     Document Type: Article

References (51)

1. Falany C.N. Enzymology of human cytosolic sulfotransferases. FASEB J 11 (1997) 206-216
2. Falany C.N., Krasnykh V., and Falany J.L. Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase. J Steroid Biochem Mol Biol 52 (1995) 529-539
3. Zhang H., Varlamova O., Vargas F.M., Falany C.N., and Leyh T.S. Sulfuryl transfer: the catalytic mechanism of human estrogen sulfotransferase. J Biol Chem 273 (1998) 10888-10892
4. Kotov A., Falany J.L., Wang J., and Falany C.N. Regulation of estrogen activity by sulfation in human Ishikawa endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol 68 (1999) 137-144
5. Falany J.L., Macrina N., and Falany C.N. Regulation of MCF-7 breast cancer cell growth by beta-estradiol sulfation. Breast Cancer Res Treat 74 (2002) 167-176
6. Li L., and Falany C.N. Elevated hepatic SULT1E1 activity in mouse models of cystic fibrosis alters the regulation of estrogen responsive proteins. J Cyst Fibrosis 6 (2007) 23-30
7. Rosenberg L.A., Schluchter M.D., Parlow A.F., and Drumm M.L. Mouse as a model of growth retardation in cystic fibrosis. Pediatr Res 59 (2006) 191-195
8. Falany J.L., Greer H., Kovacs T., Falany C.N., and Sorscher E.J. Elevation of hepatic sulphotransferase activities in mice with resistance to cystic fibrosis. Biochem J 364 (2002) 115-120
9. Welsh M.J., Tsui L.-C., Boat T.F., and Beaudet A.L. In the metabolic basis of inherited disease (1995), McGraw-Hill, New York pp. 3799-3863
10. Berschneider H.M., Knowles M.R., Azizkhan R.G., Boucher R.C., Tobey N.A., Orlando R.C., et al. Altered intestinal chloride transport in cystic fibrosis. FASEB J 2 (1988) 2625-2629
11. Trezise A.E., and Buchwald M. In vivo cell-specific expression of the cystic fibrosis transmembrane conductance regulator. Nature 353 (1991) 434-437
12. Durie P.R., Kent G., Phillips M.J., and Ackerley C.A. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol 164 (2004) 1481-1493
13. Boguszewski M.C., Kamoi T.O., Bento R.R., Boguszewski C.L., Rosberg S., Filho N.A., et al. Insulin-like growth factor-1, leptin, body composition, and clinical status interactions in children with cystic fibrosis. Hormone Res 67 (2007) 250-256
14. Ozen M., Cokugras H., Ozen N., Camcioglu Y., and Akcakaya N. Relation between serum Insulin-like growth factor-I and insulin-like growth factor-binding protein-3 levels, clinical status and growth parameters in prepubertal cystic fibrosis patients. Pediatr Int 46 (2004) 429-435
15. Leung K.C., Johannsson G., Leong G.M., and Ho K.K. Estrogen regulation of growth hormone action. Endocr Rev 25 (2004) 693-721
16. Alvaro D., Mancino M.G., Glaser S., Gaudio E., Marzioni M., Francis H., et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterol 132 (2007) 415-431
17. Rochwerger L., Dho S., Parker L., Foskett J.K., and Buchwald M. Estrogen-dependent expression of the cystic fibrosis transmembrane regulator gene in a novel uterine epithelial cell line. J Cell Sci 107 (1994) 2439-2448
18. Hardin D.S., Adams-Huet B., Brown D., Chatfield B., Dyson M., Ferkol T., et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. J Clin Endocrinol Metab 91 (2006) 4925-4929
19. Bazan J.F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci 87 (1990) 6934-6938
20. Argetsinger L.S., Campbell G.S., Yang X., Witthuhn B.A., Silvennoinen O., Ihle J.N., et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74 (1993) 237-244
21. Finidori J. Regulators of growth hormone signaling. Vitam Horm 59 (2000) 71-97
22. Herrington J., Smit L.S., Schwartz J., and Carter-Su C. The role of STAT proteins in growth hormone signaling. Oncogene 19 (2000) 2585-2597
23. Koller B.H., Kim H.S., Latour A.M., Brigman K., Boucher R.C., Scambler P., et al. Toward an animal model of cystic fibrosis: targeted interruption of exon 10 of the cystic fibrosis transmembrane regulator gene in embryonic stem cells. Proc Natl Acad Sci 88 (1991) 10730-10734
24. Du M., Jones J.R., Lanier J., Keeling K.M., Lindsey J.R., Tousson A., et al. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J Mol Med 80 (2002) 595-604
25. Falany J.L., and Falany C.N. Regulation of estrogen activity by sulfation in human MCF-7 breast cancer cells. Oncol Res 9 (1997) 589-596
26. Ratcliff R., Evans M.J., Cuthbert A.W., MacVanish L.J., Foster D., Anderson J.R., et al. Production of a severe cystic fibrosis mutation in mice by gene targeting. Nat Genet 4 (1993) 35-41
27. Christoforidis A., Maniadaki I., and Stanhope R. Growth hormone/insulin-like growth factor-1 axis during puberty. Pediatr Endocrinol Rev 3 (2005) 5-10
28. Davey H.W., Xie T., McLachlan M.J., Wilkins R.J., Waxman D.J., Grattan D.R., et al. STAT5b is required for GH-induced liver IGF-I gene expression. Endocrinology 142 (2001) 3836-3841
29. Holloway M.G., Cui Y., Laz E.V., Hosui A., Hennighausen L., and Waxman D.J. Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus. Endocrinology 148 (2007) 1977-1986
30. Phung-Koskas T., Pilon A., Pous C., Betzina C., Sturm M., Bourguet-Kondracki M.L., et al. STAT5B-mediated growth hormone signaling is organized by highly dynamic microtubules in hepatic cells. J Biol Chem 280 (2005) 1123-1131
31. Carter-Su C., King A.P., Argetsinger L.S., Smit L.S., Vanderkuur J., and Campbell G.S. Signalling pathway of GH. Endocr J 43 (1996) S65-S70
32. Waxman D.J., and O'Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol 20 (2006) 2613-2629
33. Deroo B.J., and Korach K.S. Estrogen receptors and human disease. J Clin Invest 116 (2006) 561-570
34. Fawell S.E., White R., Hoare S., Sydenham M., Page M., and Parker M.G. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci 87 (1990) 6883-6887
35. Wakeling A.E., Dukes M., and Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 51 (1991) 3867-3873
36. Wakeling A.E. Tissue-specific actions of antioestrogens. Mutat Res 333 (1995) 45-49
37. Byard P.J. The adolescent growth spurt in children with cystic fibrosis. Ann Human Biol 21 (1994) 229-240
38. Arumugam R., LeBlanc A., Seilheimer D.K., and Hardin D.S. Serum leptin and IGF-I levels in cystic fibrosis. Endocr Res 24 (1998) 247-257
39. Morison S., Dodge J.A., Cole T.J., Lewis P.A., Coles E.C., Geddes D., et al. Height and weight in cystic fibrosis: a cross sectional study. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child 77 (1997) 497-500
40. Park S.H., Wiwi C.A., and Waxman D.J. Signaling cross-talk between hepatocyte nuclear factor 4alpha and growth-hormone-activated STAT5b. Biochem J 397 (2006) 159-168
41. Venken K., Schuit F., Van L.L., Tsukamoto K., Kopchick J.J., Coschigano K., et al. Growth without growth hormone receptor: estradiol is a major growth hormone-independent regulator of hepatic IGF-I synthesis. J Bone Miner Res 20 (2005) 2138-2149
42. Leung K.C., Brce J., Doyle N., Lee H.J., Leong G.M., Sjogren K., et al. Regulation of growth hormone signaling by selective estrogen receptor modulators occurs through suppression of protein tyrosine phosphatases. Endocrinology 148 (2007) 2417-2423
43. Chen T.L., Liu F., Bates R.L., and Hintz R.L. Further characterization of insulin-like-growth factor binding proteins in rat osteoblast-like cell cultures: modulation by 17 beta-estradiol and human growth hormone. Endocrinology 128 (1991) 2489-2496
44. Hsieh Y.-C., Yu H.-P., Frink M., Suzuki T., Choudhry M.A., Schwacha M.G., et al. G protein-coupled receptor 30-dependent protein kinase A pathway is critical in nongenomic efects of estrogen in attenuating liver injury after trauma-hemorrhage. AM J Pathol 170 (2007) 1210-1218
45. Rae J.M., and Johnson M.D. What does an orphan G-protein-coupled receptor have to do with estrogen?. Breast Cancer Res 7 (2005) 243-244
46. Bjornstrom L., and Sjoberg M. Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions. Mol Endocrinol 16 (2002) 2202-2214
47. Cook D.M., Ludlam W.H., and Cook M.B. The adult growth hormone deficiency syndrome. Adv Intern Med 45 (2000) 297-315
48. Cook D.M. Growth hormone and estrogen: a clinician's approach. J Pediatr Endocrinol Metab 17 (2004) 1273-1276
49. Hardin D.S., Ahn C., Prestidge C., Seiheimer D.K., and Ellis K.J. Growth hormone improves bone mineral content in children with cystic fibrosis. J Pediatr Endocrinol Metab 18 (2005) 589-595
50. Hardin D.S., Ms-Huet B., Brown D., Chatfield B., Dyson M., Ferkol T., et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. J Clin Endocrinol Metab 91 (2006) 4925-4929
51. Colombo C., Battezzati P.M., Strazzabosco M., and Podda M. Liver and biliary problems in cystic fibrosis. Semin Liver Dis 18 (1998) 227-235